Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
10.17%
Operating Margin
5.39%
Net Margin
4.34%
Efficiency Metrics
Revenue per Expense Ratio
1.06
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
12.78%
Income Tax Rate
22.08%
EPS
1.3500000000
Balance Sheet Analysis
Current Ratio
1.83
Cash Ratio
0.26
Working Capital
$504.70M
Debt to Equity
0.10
Debt to Assets
6.63%
Equity Ratio
64.88%
Cash Flow Analysis
Operating Cash Flow Ratio
12.37%
Free Cash Flow Ratio
1.93%
CapEx to Revenue
10.43%
Dividends Paid
$63.60M
Stock Buybacks
$66.90M
Total Shareholder Returns
$130.50M
Cash Position Change
-73.45%
Key Takeaways (2023 FY)
Revenue declined by 16.738840772818%, indicating potential market challenges
Increased dividend payments by 14.57%
Detailed Growth Metrics
Core Performance
Revenue
-16.74%
Net Income
-47.90%
EPS
-47.47%
Operating Income
12.44%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-17.84%
Operating Cash Flow
-20.60%
Free Cash Flow
-178.38%
Balance Sheet Health
Assets
5.53%
Debt
40.45%
Book Value per Share
4.57%
Inventory
122.45%
Shareholder Returns
Dividends per Share
14.57%
Shares Outstanding
-0.34%
Long Term Trends
3Y Revenue/Share
20.78%
5Y Revenue/Share
10.30%
3Y Dividend/Share
-84.10%
5Y Dividend/Share
56.00%